USANA HEALTH SCIENCES INC
For the period ended Sep 28, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 28, 2024 · Filed Nov 5, 2024
USNA$13.10-5.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
For the nine months ended September 30, 2023
| Common Stock · AdditionalPaid-inCapital · RetainedEarnings · AccumulatedOtherComprehensiveIncome (Loss) · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Value | |||||||||
| Balance at December 31, 2022 | 19,206 | $19 | $55,604 | $391,636 | $(12,787) | $434,472 | |||
| Net earnings | 47,022 | 47,022 | |||||||
| Other comprehensive income (loss), net of tax | (7,437) | (7,437) | |||||||
| Equity-based compensation expense | 10,952 | 10,952 | |||||||
| Common stock repurchased and retired | (180) | — | (1,446) | (10,211) | (11,657) | ||||
| Common stock issued under equity award plans | 96 | — | — | ||||||
| Tax withholding for net-share settled equity awards | (2,958) | (2,958) | |||||||
| Balance at September 30, 2023 | 19,122 | $19 | $62,152 | $428,447 | $(20,224) | $470,394 | |||
For the nine months ended September 28, 2024
| Common Stock · AdditionalPaid-inCapital · RetainedEarnings · AccumulatedOtherComprehensiveIncome (Loss) · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Value | |||||||||
| Balance at December 30, 2023 | 19,130 | $19 | $65,661 | $445,217 | $(13,695) | $497,202 | |||
| Net earnings | 37,576 | 37,576 | |||||||
| Other comprehensive income (loss), net of tax | (4) | (4) | |||||||
| Equity-based compensation expense | 10,945 | 10,945 | |||||||
| Common stock repurchased and retired | (194) | — | (1,180) | (8,303) | (9,483) | ||||
| Common stock issued under equity award plans | 120 | — | — | ||||||
| Tax withholding for net-share settled equity awards | (3,149) | (3,149) | |||||||
| Balance at September 28, 2024 | 19,056 | $19 | $72,277 | $474,490 | $(13,699) | $533,087 | |||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
For the three months ended September 30, 2023
| Common Stock · AdditionalPaid-inCapital · RetainedEarnings · AccumulatedOtherComprehensiveIncome (Loss) · Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Value | ||||||||||
| Balance at July 1, 2023 | 19,298 | $19 | $59,970 | $427,311 | $(18,476) | $468,824 | ||||
| Net earnings | 11,347 | 11,347 | ||||||||
| Other comprehensive income (loss), net of tax | (1,748) | (1,748) | ||||||||
| Equity-based compensation expense | 3,670 | 3,670 | ||||||||
| Common stock repurchased and retired | (180) | — | (1,446) | (10,211) | (11,657) | |||||
| Common stock issued under equity award plans | 4 | — | — | |||||||
| Tax withholding for net-share settled equity awards | (42) | (42) | ||||||||
| Balance at September 30, 2023 | 19,122 | $19 | $62,152 | $428,447 | $(20,224) | $470,394 | ||||
For the three months ended September 28, 2024
| Common Stock · AdditionalPaid-inCapital · RetainedEarnings · AccumulatedOtherComprehensiveIncome (Loss) · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Value | ||||||||
| Balance at June 29, 2024 | 19,051 | $19 | $68,814 | $463,883 | $(20,508) | $512,208 | ||
| Net earnings | 10,607 | 10,607 | ||||||
| Other comprehensive income (loss), net of tax | 6,809 | 6,809 | ||||||
| Equity-based compensation expense | 3,542 | 3,542 | ||||||
| Common stock issued under equity award plans | 5 | — | — | |||||
| Tax withholding for net-share settled equity awards | (79) | (79) | ||||||
| Balance at September 28, 2024 | 19,056 | $19 | $72,277 | $474,490 | $(13,699) | $533,087 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.